Home › Funds › NEXTBio Capital Management LP › STTK
NEXTBio Capital Management LP position in STTK
SHATTUCK LABS INC · Health Care
NEXTBio Capital Management LP reported holding 3,727,348 shares of STTK (SHATTUCK LABS INC) in its Q3 2026 13F filing — a position valued at US$25.4M, representing 11.07% of its reported portfolio and ranking #2 among its reported holdings. NEXTBio Capital Management LP has disclosed STTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's STTK position evolved
NEXTBio Capital Management LP first disclosed a stake in STTK in Q4 2025 at 3,149,907 shares (US$11.5M). The position peaked in Q2 2026 at 3,727,348 shares, worth US$25.9M. Across 4 filings, NEXTBio Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 3,727,348 shares valued at US$25.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 3.15M | $11.50M | New |
| Q1 2026 | 3.15M | $20.25M | Hold |
| Q2 2026 | 3.73M | $25.87M | Add |
| Q3 2026 | 3.73M | $25.42M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STTK and 13F data
STTK (SHATTUCK LABS INC) is a Health Care company. 59 other funds we track also report a position in STTK — the largest reported positions include Redmile Group, LLC (US$47.8M), ORBIMED ADVISORS LLC (US$43.8M), Prosight Management, LP (US$41.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STTK
- Redmile Group, LLC 6.89M sh · $47.83M · Q2 2026
- ORBIMED ADVISORS LLC 6.31M sh · $43.76M · Q2 2026
- Prosight Management, LP 5.96M sh · $41.35M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.75M sh · $26.02M · Q2 2026
- Deep Track Capital, LP 3.71M sh · $25.72M · Q2 2026
- CLARK ESTATES INC/NY 1.42M sh · $9.66M · Q3 2026
- Boxer Capital Management, LLC 1.00M sh · $6.94M · Q2 2026
- S&G Foundation 435.75K sh · $2.97M · Q3 2026
- West Tower Group, LLC 191.62K sh · $1.31M · Q3 2026
- LBJ Family Wealth Advisors, Ltd. 82.18K sh · $560.00K · Q3 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held STTK?
NEXTBio Capital Management LP has disclosed STTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in STTK?
As of Q3 2026, NEXTBio Capital Management LP holds 3.73M shares of STTK (SHATTUCK LABS INC), valued at $25.42M, representing 11.07% of its reported portfolio and ranking #2.
Has NEXTBio Capital Management LP been buying or selling STTK?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in STTK. The position peaked in Q2 2026 at 3.73M shares.
Which other funds hold STTK?
Other major institutional holders of STTK include Redmile Group, LLC, ORBIMED ADVISORS LLC, Prosight Management, LP, among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.